The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease
Abstract
Neural injury leads to inflammation and activation of microglia that in turn may participate in progression of neurodegeneration. The mechanisms involved in changing microglial activity from beneficial to chronic detrimental neuroinflammation are not known but reactive oxygen species (ROS) may be involved. We have addressed this question in Nrf2‐knockout mice, with hypersensitivity to oxidative stress, submitted to daily inoculation of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) for 4 weeks. Basal ganglia of these mice exhibited a more severe dopaminergic dysfunction than wild type littermates in response to MPTP. The amount of CD11b‐positive/CD45‐highly‐stained cells, indicative of peripheral macrophage infiltration, did not increase significantly in response to MPTP. However, Nrf2‐deficient mice exhibited more astrogliosis and microgliosis as determined by an increase in messenger RNA and protein levels for GFAP and F4/80, respectively. Inflammation markers characteristic of classical microglial activation, COX‐2, iNOS, IL‐6, and TNF‐α were also increased and, at the same time, anti‐inflammatory markers attributable to alternative microglial activation, such as FIZZ‐1, YM‐1, Arginase‐1, and IL‐4 were decreased. These results were confirmed in microglial cultures stimulated with apoptotic conditioned medium from MPP+‐treated dopaminergic cells, further demonstrating a role of Nrf2 in tuning balance between classical and alternative microglial activation. This study demonstrates a crucial role of Nrf2 in modulation of microglial dynamics and identifies Nrf2 as molecular target to control microglial function in Parkinson's disease (PD) progression. © 2009 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Malhotra, D., Thimmulappa, R., Navas-Acien, A., Sandford, A., Elliott, M., Singh, A., Chen, L., Zhuang, X., Hogg, J., Pare, P., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200803-380oc · Cited by 357
RetractedExploring the full spectrum of macrophage activation
Mosser, D. M., & Edwards, J. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2448 · Cited by 9,144
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
Molecular Pathways of Neurodegeneration in Parkinson's Disease
Dawson, T. M., & Dawson, V. L. (2003) · Science · doi:10.1126/science.1087753 · Cited by 1,663
MOLECULAR PATHOPHYSIOLOGY OF PARKINSON'S DISEASE
Moore, D. J., West, A. B., Dawson, V. L., & Dawson, T. M. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135718 · Cited by 1,280
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183
Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis
Thimmulappa, R. K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25790 · Cited by 1,028 · cited 1×
“The relevance of Nrf2 in modulation of the innate immune system has been suggested in models of acute inflammation induced by lipolysaccharide (Innamorato et al., 2008; Rangasamy et al., 2004, 2005; Thimmulappa et al., 2006).”
BackgroundGenetic ablation of Nrf2 enhances susceptibility to cigarette smoke–induced emphysema in mice
Rangasamy, T., Cho, C. Y., Thimmulappa, R. K., Zhen, L., Srisuma, S. S., Kensler, T. W., Yamamoto, M., Petrache, I., Tuder, R. M., & Biswal, S. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421146 · Cited by 991
Self-citationWhy neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression
Gao, H.-M., & Hong, J.-S. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.05.002 · Cited by 821
Clements, C. M., McNally, R. S., Conti, B. J., Mak, T. W., & Ting, J. P.-Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607260103 · Cited by 818
KUSHNAREVA, Y., MURPHY, A. N., & ANDREYEV, A. (2002) · Biochemical Journal · doi:10.1042/bj20021121 · Cited by 677
The Nrf2–ARE Pathway: An Indicator and Modulator of Oxidative Stress in Neurodegeneration
Johnson, J. A., Johnson, D. A., Kraft, A. D., Calkins, M. J., Jakel, R. J., Vargas, M. R., & Chen, P. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.036 · Cited by 589
Sherer, T. B., Betarbet, R., Stout, A. K., Lund, S., Baptista, M., Panov, A. V., Cookson, M. R., & Greenamyre, J. T. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-16-07006.2002 · Cited by 581
Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice
Rangasamy, T., Guo, J., Mitzner, W. A., Roman, J., Singh, A., Fryer, A. D., Yamamoto, M., Kensler, T. W., Tuder, R. M., Georas, S. N., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050538 · Cited by 580
Self-citationChen, P.-C., Vargas, M. R., Pani, A. K., Smeyne, R. J., Johnson, D. A., Kan, Y. W., & Johnson, J. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813361106 · Cited by 579
Jenner, P., Dexter, D. T., Sian, J., Schapira, A. H. V., Marsden, C. D., & The Royal Kings And Queens Parkinson's Disease Research Group (1992) · Annals of Neurology · doi:10.1002/ana.410320714 · Cited by 544
Salazar, M., Rojo, A. I., Velasco, D., de Sagarra, R. M., & Cuadrado, A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513737200 · Cited by 521
Self-citationThe Transcription Factor Nrf2 Is a Therapeutic Target against Brain Inflammation
Innamorato, N. G., Rojo, A. I., García-Yagüe, À. J., Yamamoto, M., de Ceballos, M. L., & Cuadrado, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.680 · Cited by 480
Self-citationOxidative Stress in Parkinson's Disease: A Mechanism of Pathogenic and Therapeutic Significance
Zhou, C., Huang, Y., & Przedborski, S. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.023 · Cited by 450
Cicchetti, F., Brownell, A. L., Williams, K., Chen, Y. I., Livni, E., & Isacson, O. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.01938.x · Cited by 406
Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD.
(2006) · Journal of Neuroinflammation · doi:10.1186/1742-2094-3-27 · Cited by 393
Bioenergetic and oxidative stress in neurodegenerative diseases
Bowling, A. C., & Beal, M. F. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00055-b · Cited by 366
Bosco, D. A., Fowler, D. M., Zhang, Q., Nieva, J., Powers, E. T., Wentworth, P., Lerner, R. A., & Kelly, J. W. (2006) · Nature Chemical Biology · doi:10.1038/nchembio782 · Cited by 349
Zhou, W., & Freed, C. R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507124200 · Cited by 346
Clausen, B. H., Lambertsen, K. L., Babcock, A. A., Holm, T. H., Dagnaes-Hansen, F., & Finsen, B. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-46 · Cited by 315
Oxidative damage in nucleic acids and Parkinson's disease
Nakabeppu, Y., Tsuchimoto, D., Yamaguchi, H., & Sakumi, K. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21191 · Cited by 290
Cassarino, D. S., Fall, C. P., Swerdlow, R. H., Smith, T. S., Halvorsen, E. M., Miller, S. W., Parks, J. P., Parker, W. D., & Bennett, J. P. (1997) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(97)00070-7 · Cited by 265
Age-dependent Motor Deficits and Dopaminergic Dysfunction in DJ-1 Null Mice
Chen, L., Cagniard, B., Mathews, T., Jones, S., Koh, H. C., Ding, Y., Carvey, P. M., Ling, Z., Kang, U. J., & Zhuang, X. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413955200 · Cited by 261
Min, K.-J., Yang, M.-S., Kim, S.-U., Jou, I., & Joe, E.-H. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3696-05.2006 · Cited by 257
Glutathione and Parkinson's disease: Is this the elephant in the room?
Zeevalk, G. D., Razmpour, R., & Bernard, L. P. (2008) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2008.01.017 · Cited by 212
The pathogenesis of cell death in Parkinson's disease – 2007
Olanow, C. W. (2007) · Movement Disorders · doi:10.1002/mds.21675 · Cited by 211
The transcription factor Nrf2 as a new therapeutic target in Parkinson's disease
Cuadrado, A., Moreno-Murciano, P., & Pedraza‐Chaverrí, J. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/13543780802716501 · Cited by 145
Self-citationHu, X., Zhang, D., Pang, H., Caudle, W. M., Li, Y., Gao, H., Liu, Y., Li, Q., Wilson, B. C., Monte, D. A. D., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.7194 · Cited by 133
Iron metabolism and Parkinson's disease.
Hirsch, É. C., & Faucheux, B. A. (1998) · PubMed · Cited by 124
Modifications of the iron–neuromelanin system in Parkinson's disease
Fasano, M., Bergamasco, B., & Lopiano, L. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03638.x · Cited by 117
Gene-environment interactions in parkinsonism and Parkinson’s disease: the Geoparkinson study
Dick, F. D., Palma, G. D., Ahmadi, A., Osborne, A., SCOTT, N. W., Prescott, G. J., Bennett, J. B., Semple, S. E., Dick, F. D., Mozzoni, P., et al. (2007) · Occupational and Environmental Medicine · doi:10.1136/oem.2006.032078 · Cited by 105
Choi, H. K., Won, L., Roback, J. D., Wainer, B. H., & Heller, A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.8943 · Cited by 96
Clark, J., & Simon, D. K. (2008) · Antioxidants and Redox Signaling · doi:10.1089/ars.2008.2241 · Cited by 95
De Haas, A. H., Boddeke, H. W. G. M., Brouwer, N., & Biber, K. (2007) · Glia · doi:10.1002/glia.20554 · Cited by 81
Ibuprofen and apigenin induce apoptosis and cell cycle arrest in activated microglia
Elsisi, N. S., Darling‐Reed, S., Lee, E.-S., Oriaku, E. T., & Soliman, K. F. A. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.10.087 · Cited by 70
Inflammation and infection in Parkinson's disease.
Arai, H., Furuya, T., Mizuno, Y., & Mochizuki, H. (2006) · PubMed · doi:10.14670/hh-21.673 · Cited by 62
Association of a polymorphism in the ABCB1 gene with Parkinson's disease
Westerlund, M., Belin, A. C., Anvret, A., Håkansson, A. S., Nissbrandt, H., Lind, C., Sydow, O., Olson, L., & Galter, D. (2009) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.11.010 · Cited by 46
Inflammation in Parkinson's disease: an update.
Smith, P. F. (2008) · PubMed · Cited by 41
Ibuprofen and the mouse model of Parkinson's disease
Kurkowska‐Jastrzębska, I., Członkowski, A., & Członkowska, A. (2006) · Annals of Neurology · doi:10.1002/ana.20860 · Cited by 14
Cited by
Nrf2 signaling pathway: pivotal roles in inflammation
Ahmed, S. M. U., Luo, L., Namani, A., Wang, X. J., & Tang, X. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.11.005 · Cited by 1,794
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
Cuadrado, A., Rojo, A. I., Wells, G., Hayes, J. D., Cousin, S. P., Rumsey, W. L., Attucks, O. C., Franklin, S., Levonen, A.-L., Kensler, T. W., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0008-x · Cited by 1,438
Self-citationAn Overview of Nrf2 Signaling Pathway and Its Role in Inflammation
Saha, S., Buttari, B., Panieri, E., Profumo, E., & Saso, L. (2020) · Molecules · doi:10.3390/molecules25225474 · Cited by 1,388
Simpson, D. S. A., & Oliver, P. L. (2020) · Antioxidants · doi:10.3390/antiox9080743 · Cited by 1,044
“In microglia, Nrf2-deficiency promotes inflammatory marker expression (IL6, Cox2, iNOS) whilst inhibiting anti-inflammatory marker expression (arginase 1, IL4) in response to LPS and MPTP [168,169].”
BackgroundReactive Oxygen Species: Drivers of Physiological and Pathological Processes
Checa, J., & Aran, J. M. (2020) · Journal of Inflammation Research · doi:10.2147/jir.s275595 · Cited by 984
Metadata
- Authors
- Rojo, A. I., Innamorato, N. G., Martín‐Moreno, A. M., De Ceballos, M. L., Yamamoto, M., & Cuadrado, A.
- Venue
- Glia
- Publisher
- Wiley
- Published
- 2009-11-11
- Volume
- 58
- Issue
- 5
- Pages
- 588-598
- ISSN
- 0894-1491 (ISSN-L)
- 1098-1136
- OpenAlex
- W2135716022
- Cited by
- 375
- References
- 46
- FWCI
- 8.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.